Boardroom Alpha
Boardroom Alpha
SLS · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Sellas Life Sciences Group Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
SLS
Accession
0001104659-26-047697
Boardroom Alpha · Filing insights

Sellas Life Sciences' board urges voting For all 2026 annual meeting proposals, including director elections and equity-plan increase.

About Sellas Life Sciences Group Inc
Market cap
$1.5B
1Y TSR
+312.0%
3Y TSR
+61.5%
Board grade
C-
Sector
Healthcare
CEO
Andelos M Stergiou
Last annual meeting: Jun 16, 2026 · View full Sellas Life Sciences Group Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

 

Filed by the Registrant x Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement

 

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨ Definitive Proxy Statement

 

x Definitive Additional Materials

 

¨ Soliciting Material Pursuant to § 240.14a-12

 

SELLAS LIFE SCIENCES GROUP, INC.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x No fee required.

 

¨ Fee previously paid with preliminary materials.

 

¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

 

GRAPHIC

Your Vote Counts! SELLAS LIFE SCIENCES GROUP, INC. 2026 Annual Meeting Vote by June 15, 2026 11:59 PM ET You invested in SELLAS LIFE SCIENCES GROUP, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 16, 2026. Vote Virtually at the Meeting* June 16, 2026 8:30 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/SLS2026 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V86702-P48673 SELLAS LIFE SCIENCES GROUP, INC. 7 TIMES SQUARE, SUITE 2503 NEW YORK, NEW YORK 10036 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by request prior to June 2, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V86703-P48673 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. We encourage you to access and review the complete proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. 1. The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders. Nominees: 1a. Robert Van Nostrand For 1b. Jane Wasman For 2. The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve an amendment to the Company’s 2023 Amended and Restated Equity Incentive plan (the “2023 Equity Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2023 Equity Plan by 20,000,000 shares. For 4. The advisory approval of the compensation of our named executive officers. For 5. The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to adopt the proposals set forth above or to establish a quorum. For

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Sellas Life Sciences Group Inc (SLS)

Reference

Frequently asked questions

When did Sellas Life Sciences Group Inc file this DEFA14A?
Sellas Life Sciences Group Inc (SLS) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001104659-26-047697.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Sellas Life Sciences' board urges voting For all 2026 annual meeting proposals, including director elections and equity-plan increase. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Sellas Life Sciences Group Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Sellas Life Sciences Group Inc has filed under CIK 1390478, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer